|Articles|October 16, 2019
Treatment of Plaque Psoriasis
On August 1 2019, the U.S. Food and Drug Administration (FDA) expanded the approved indication for Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older. The decision is supported, in part, by the Enstilar Pediatric Study (NCT02387853) in adolescents age 12 to 17 with psoriasis of the body and scalp.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Content
Latest CME
Trending on Dermatology Times
1
Sister Clinicians Highlight Cross-Specialty Collaboration in Dermatology and Podiatry
2
Expert Tips for Treating Vitiligo Shared at Elevate-Derm Conference
3
A Dual mRNA Vaccine Against Merkel Cell Carcinoma Shows Synergy with PD-1 Blockade
4
Tips for Improving Rosacea Recognition in Patients With Skin of Color at Elevate-Derm
5
